Platelet Transfusions in the Infant and Child

Handbook of Pediatric Transfusion Medicine

Volumn , Issue , 2004, Pages 253-269

  Saxonhouse, Matthew ^a   Slayton, William ^a   Sola, Martha C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941627991     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012348776-6/50025-X     Document Type: Chapter

References (180)

1. Aballi AJ, Puapondh Y, et al. Platelet counts in thriving premature infants. Pediatrics 1968, 42:685-689.
2. Abzug MJ, Levin MJ Neonatal adenovirus infection: four patients and review of the literature. Pediatrics 1991, 87:890-896.
3. Albert J, Norman M, et al. Inhaled nitric oxide does not influence bleeding time or platelet function in healthy volunteers. Eur J Clin Invest 1999, 29:953-959.
4. Albert J, Wallen NH, et al. Neither endogenous nor inhaled nitric oxide influencesthe function of circulating platelets in healthy volunteers. Clin Sci (Lond) 1999, 97:345-353.
5. Albert J, Wallen NH, et al. Effects of inhaled nitric oxide compared with aspirin on platelet function in vivo in healthy subjects. Clin Sci (Lond) 1996, 91:225-231.
6. Alter BP Aplastic anemia, pediatric aspects. Oncologist 1996, 1:361-366.
7. Alter BP Arm anomalies and bone marrow failure may go hand in hand. J Hand Surg [Am] 1992, 17:566-571.
8. Andrew M, Castle V, et al. Modified bleeding time in the infant. Am J Hematol 1989, 30:190-191.
9. Andrew M, Castle V, et al. Clinical impact of neonatal thrombocytopenia. J Pediatr 1987, 110:457-464.
10. Andrew M, Kelton J Neonatal thrombocytopenia. Clin Perinatol 1984, 11:359-391.
11. Andrew M, Paes B, et al. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990, 12:95-104.
12. Andrew M, Paes B, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988, 72:1651-1657.
13. Andrew M, Vegh P, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993, 123:285-291.
14. Auerbach AD, Verlander PC, et al. New molecular diagnostic tests for two congenital forms of anemia. J Clin Lab Anal 1997, 11:17-22.
15. Balduini CL, Iolascon A, et al. Inherited thrombocytopenias: from genes to therapy. Haematologica 2002, 87:860-880.
16. Basser RL, Rasko JE, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997, 89:3118-3128.
17. Basser RL, Rasko JE, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996, 348:1279-1281.
18. Bennett JS, Kolodziej MA Disorders of platelet function. Dis Mon 1992, 38:577-631.
19. Bjerke HS, Kelly RE, et al. Decreasing transfusion exposure risk during extracorporeal membrane oxygenation (ECMO). Transfus Med 1992, 2:43-49.
20. Blackburn SC, Oliart AD, et al. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998, 18:1277-1283.
21. Blade J, Gaston F, et al. Spinal subarachnoid hematoma after lumbar puncture causing reversible paraplegia in acute leukemia. Case report. J Neurosurg 1983, 58:438-439.
22. Blajchman MA, Goldman M, et al. Proceedings of a consensus conference: prevention of posttransfusion CMV in the era of universal leukoreduction. Transfus Med Rev 2001, 15:1-20.
23. Blanchette VS Neonatal alloimmune thrombocytopenia: a clinical perspective. Curr Stud Hematol Blood Transfus 1988, 54:112-126.
24. Blanchette VS, Hume HA, et al. Guidelines for auditing pediatric blood transfusion practices. Am J Dis Child 1991, 145:787-796.
25. Blanchette VS, Johnson J, et al. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol 2000, 13:365-390.
26. Blanchette VS, Kuhne T, et al. Platelet transfusion therapy in newborn infants. Transfus Med Rev 1995, 9:215-230.
27. Bowden RA, Sayers M, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986, 314:1006-1010.
28. Bowden RA, Slichter SJ, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991, 78:246-250.
29. Braithwaite K, Abu-Ghosh A, et al. Treatment of severe thrombocytopenia with IL-11 in children with Wiskott-Aldrich syndrome. J Pediatr Hematol Oncol 2002, 24:323-326.
30. Brecher ME, Holland PV, et al. Growth of bacteria in inoculated platelets: implications for bacteria detection and the extension of platelet storage. Transfusion 2000, 40:1308-1312.
31. Brecher ME, Means N, et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 2001, 41:477-482.
32. Brecher ME, Moore SB, et al. Posttransfusion purpura: the therapeutic value of PlA1-negative platelets. Transfusion 1990, 30:433-435.
33. Buchholz DH, Young VM, et al. Bacterial proliferation in platelet products stored at room temperature. Transfusion-induced Enterobacter sepsis. N Engl J Med 1971, 285:429-433.
34. Bussel JB, Mukherjee R, et al. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 2001, 66:172-177.
35. Calhoun DA, Christensen RD, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000, 27:733-753.
36. Calpin C, Dick P, et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia?. Arch Pediatr Adolesc Med 1998, 152:345-347.
37. Carr R, Hutton JL, et al. Transfusion of ABO-ismatched platelets lead to early platelet refractoriness. Br J Haematol 1990, 75:408-413.
38. Castle V, Andrew M, et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986, 108:749-755.
39. Centers for Disease Control and Prevention Investigations of West Nile virus infections in recipients of blood transfusions. JAMA 2002, 288:2535-2536.
40. Cheung PY, Sawick G, et al. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Crit Care Med 2000, 28:2584-2590.
41. Chevuru SC, Sola MC, et al. Multicenter analysis of platelet transfusion usage among neonates on extracorporeal membrane oxygenation. Pediatrics 2002, 109:e89.
42. Christou H, Magnani B, et al. Inhaled nitric oxide does not affect adenosine 5' diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn. Pediatrics 1998, 102:1390-1393.
43. Corazza MS, Davis RF, et al. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr 1984, 105:292-296.
44. Couban S, Carruthers J, et al. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion 2002, 42:753-758.
45. Davis KB, Slichter SJ, et al. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 1999, 39:586-592.
46. DelVecchio A, Sola MC, et al. Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 2001, 41:803-808.
47. Dela Cruz TV, Stewart DL, et al. Risk factors for intracranial hemorrhage in the extracorporeal membrane oxygenation patient. J Perinatol 1997, 17:18-23.
48. Dodd RY Viral contamination of blood components and approaches for reduction of infectivity. Immunol Invest 1995, 24:25-48.
49. Duquesnoy RJ, Filip DJ, et al. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977, 2:219-226.
50. Dzik WH, Anderson JK, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002, 42:1114-1122.
51. Edelson RN, Chernik NL, et al. Spinal subdural hematomas complicating lumbar puncture. Arch Neurol 1974, 31:134-137.
52. Eisenfeld L, Silver H, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992, 32:205-209.
53. Fanucchi M, Glaspy J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409.
54. Feusner J. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. The use of platelet transfusions. Am J Pediatr Hematol Oncol 1984, 6:255-260.
55. Finsterer J, Pelzl G, et al. Severe, isolated thrombocytopenia under polytherapy with carbamazepine and valproate. Psychiatry Clin Neurosci 2001, 55:423-426.
56. Friedman Z, Whitman V, et al. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol 1978, 18:272-279.
57. Garcia MG, Duenas E, et al. Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 2001, 21:415-420.
58. Gelb AB, Leavitt AD Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997, 37:624-630.
59. George D, Bussel JB Neonatal thrombocytopenia. Semin Thromb Hemost 1995, 21:276-293.
60. George TN, Johnson KJ, et al. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 1998, 132:731-734.
61. Gesundheit B, Kirby M, et al. Thrombocytopenia and megakary-ocyte dysplasia: an adverse effect of valproic acid treatment. J Pediatr Hematol Oncol 2002, 24:589-590.
62. Gilbert GL, Hayes K, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1989, 1:1228-1231.
63. Goldman SC, Bracho F, et al. Feasibility study of IL-11 and granulocyte colony stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. J Pediatr Hematol Oncol 2001, 23:300-305.
64. Gordon LI, Kwaan HC, et al. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987, 24:194-201.
65. Gries A, Bode C, et al. Inhaled nitric oxide inhibits human platelet aggregation, P selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 1998, 97:1481-1487.
66. Gries A, Herr A, et al. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers. Thromb Haemost 2000, 83:309-315.
67. Hanigan WC, Kennedy G, et al. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates. J Pediatr 1988, 112:941-947.
68. Heddle NM, Klama L, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994, 331:625-628.
69. Herman JH, Kamel HT Platelet transfusion. Current techniques, remaining problems, and future prospects. Am J Pediatr Hematol Oncol 1987, 9:272-286.
70. Higby DJ, Cohen E, et al. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 1974, 14:440-446.
71. Homans A Thrombocytopenia in the neonate. Pediatr Clin North Am 1996, 43:737-756.
72. Howard SC, Gajjar A, et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 2000, 284:2222-2224.
73. Isaacs C, Robert NJ, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997, 15:3368-3377.
74. Israels SJ, Daniels M, et al. Deficient collagen-induced activation in the newborn platelet. Pediatr Res 1990, 27:337-343.
75. Israels SJ, Odaibo FS, et al. Deficient thromboxane synthesis and response in platelets from premature infants. Pediatr Res 1997, 41:218-223.
76. Iyori H, Bessho F, et al. Intracranial hemorrhage in children with immune thrombocytopenic purpura. Japanese Study Group on childhood ITP. Ann Hematol 2000, 79:691-695.
77. Jubelirer SJ, Harpold R The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 2002, 8:73-76.
78. Kao GS, Wood IG, et al. Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion 2003, 43:185-191.
79. Kaplan C, Morel-Kopp MC, et al. HPA-b (Br(a)) neonatal alloimmunethrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991, 78:425-429.
80. Kaushansky K, Broudy VC, et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A 1995, 92:3234-3238.
81. Klaassen RJ, Doyle JJ, et al. Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis. J Pediatr Hematol Oncol 2001, 23:511-518.
82. Klein HG, Dodd RY, et al. Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997, 37:95-101.
83. Kluter H, Bubel S, et al. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999, 39:1179-1184.
84. Kroll H, Muntean W, et al. Anti Ko(a) as a cause of neonatal alloimmune thrombocytopenia. Beitr Infusionsther Transfusionsmed 1994, 32:244-246.
85. Kuehnert MJ, Roth VR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001, 41:1493-1499.
86. Lang DJ, Ebert PA, et al. Reduction of postperfusion cytomegalovirus infections following the use of leukocyte depleted blood. Transfusion 1977, 17:397-405.
87. Lawrence JB, Yomtovian RA, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 2001, 41:67-76.
88. Lee EJ, Schiffer CA ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989, 29:384-389.
89. Lee PI, Chang MH, et al. Transfusion-acquired cytomegalovirus infection in children in a hyperendemic area. J Med Virol 1992, 36:49-53.
90. Lilleyman JS Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1983, 54:11-14.
91. Liu HW, Yuen KY, et al. Reduction of platelet transfusion-associated sepsis by short-term bacterial culture. Vox Sang 1999, 77:1-5.
92. Lonial S, Bilodeau PA, et al. Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature. Bone Marrow Transplant 1999, 24:1337-1341.
93. Luban NL Not just a small adult. Transfusion 2002, 42:666-668.
94. Lupton BA, Hill A, et al. Reduced platelet count as a risk factor for intraventricular hemorrhage. Am J Dis Child 1988, 142:1222-1224.
95. Maher P, Lane B, et al. Does indomethacin cause extension of intracranial hemorrhages: a preliminary study. Pediatrics 1985, 75:497-500.
96. Manoharan A, Williams NT, et al. Acquired amegakaryocytic thrombocytopenia: report of a case and review of literature. Q J Med 1989, 70:243-252.
97. Massey GV, McWilliams NB, et al. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987, 111:133-135.
98. McCann SR, Bacigalupo A, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994, 13:233-237.
99. Medeiros D, Buchanan GR Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 1998, 133:334-339.
100. Mehta P, Vasa R, et al. Thrombocytopenia in the high-risk infant. J Pediatr 1980, 97:791-794.
101. Ment LR Intraventricular hemorrhage of the preterm neonate: prevention studies. Mead Johnson Symp Perinat Dev Med 1988, 19-26.
102. Ment LR, Duncan CC, et al. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants. J Pediatr 1985, 107:937-943.
103. Ment LR, Oh W, et al. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. J Pediatr 1994, 124:951-955.
104. Miller WJ, McCullough J, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991, 7:234-277.
105. Minifee PK, Daeschner CW, et al. Decreasing blood donor exposure in neonates on extracorporeal membrane oxygenation. J Pediatr Surg 1990, 25:38-42.
106. Murphy S, Gardner FH Effect of storage temperature on maintenance of platelet viability-deleterious effect of refrigerated storage. N Engl J Med 1969, 280:1094-1098.
107. Murphy S, Litwin S, et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982, 12:347-356.
108. Murray NA Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Acta Paediatr Suppl 2002, 91:74-81.
109. Murray NA, Howarth LJ, et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002, 12:35-41.
110. Muylle L, Wouters E, et al. Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Transfusion 1996, 36:886-890.
111. Ness P, Braine H, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001, 41:857-861.
112. Nishizawa EE, Wynalda DJ Inhibitory effect of ibuprofen (Motrin) on platelet function. Thromb Res 1981, 21:347-356.
113. Nomura S, Dan K, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002, 100:728-730.
114. Nonoyama S Wiskott-Aldrich syndrome (role of WASP). J Med Dent Sci 2001, 48:1-6.
115. Noris M, Remuzzi G Uremic bleeding: closing the circle after 30 years of controversies?. Blood 1999, 94:2569-2574.
116. Ohto H, Anderson KC Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion 1996, 36:117-123.
117. Oren H, Irken G, et al. Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia. Indian J Pediatr 1994, 61:551-558.
118. Patnode NM, Gandhi PJ Drug-induced thrombocytopenia in the coronary care unit. J Thromb Thrombolysis 2000, 10:155-167.
119. Pierce RN, Reich LM, et al. Hemolysis following platelet transfusions from ABO incompatible donors. Transfusion 1985, 25:60-62.
120. Pink JM, MacCallum S, et al. Platelet transfusion-related sepsis. Aust N Z J Med 1993, 23:717.
121. Pisciotto PT, Benson K, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995, 35:498-502.
122. Preiksaitis JK, Brown L, et al. Transfusion-acquired cytomegalovirus infection in neonates. A prospective study. Transfusion 1988, 28:205-209.
123. Ragni MV, Miller BJ, et al. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J Hematol 1992, 40:176-182.
124. Rajasekhar D, Kestin AS, et al. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost 1994, 72:957-963.
125. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 2001, 8:249-254.
126. Roback JD Platelets and related products. Handbook of transfusion medicine 2001, Academic Press, San Diego.
127. Roberts IA, Murray NA Management of thrombocytopenia in neonates. Br J Haematol 1999, 105:864-870.
128. Robinson TM, Kickler TS, et al. Effect of extracorporeal membrane oxygenation on platelets in newborns. Crit Care Med 1993, 21:1029-1034.
129. Roseff SD, Luban NL, et al. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002, 42:1398-1413.
130. Rosenberg EM, Chambers LA, et al. A program to limit donor exposures to neonates undergoing extracorporeal membrane oxygenation. Pediatrics 1994, 94:341-346.
131. Roy AJ, Jaffe N, et al. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 1973, 13:283-290.
132. Roy V, Verfaillie CM Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature. Bone Marrow Transplant 1996, 17:115-117.
133. Samama CM, Diaby M, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1995, 83:56-65.
134. Sanders MR, Graeber JE Posttransfusion graft-versus-host disease in infancy. J Pediatr 1990, 117:159-163.
135. Schiffer CA, Lee EJ, et al. Clinical evaluation of platelet concentrates stored for one to five days. Blood 1986, 67:1591-1594.
136. Schroeder ML Transfusion-associated graft-versus-host disease. Br J Haematol 2002, 117:275-287.
137. Sidiropoulos D, Straume B The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i.v.). Blut 1984, 48:383-386.
138. Silliman CC, Boshkov LK, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003, 101:454-462.
139. Silliman CC, Paterson AJ, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997, 37:719-726.
140. Silvergleid AJ, Hafleigh EB, et al. Clinical value of washedplatelet concentrates in patients with non-hemolytic transfusion reactions. Transfusion 1977, 17:33-37.
141. Simon TL, Sierra ER Concentration of platelet units into small volumes. Transfusion 1984, 24:173-175.
142. Simpson MB Prospective-concurrent audits and medical consultation for platelet transfusions. Transfusion 1987, 27:192-195.
143. Sloand EM, Fox S, et al. Preparation of IgA-deficient platelets. Transfusion 1990, 30:322-326.
144. Smith JW Tolerability and side-effect profile of rhIL-11. Oncology (Huntingt) 2000, 14:41-47.
145. Sola MC, Christensen RD, et al. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000, 47:208-214.
146. Sola MC, Du Y, et al. Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and nonthrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000, 110:449-453.
147. Sola MC, Dame C, et al. Toward a rational use of recombinant thrombopoietin in the neonatal intensive care unit. J Pediatr Hematol Oncol 2001, 23:179-184.
148. Sola MC, del Vecchio A, et al. The relationship between hematocrit and bleeding time in very low birth weight infants during the first week of life. J Perinatol 2001, 21:368-371.
149. Strauss RG Blood banking and transfusion issues in perinatal medicine. Hematologic problems of the neonate 2000, W.B. Saunders, Philadelphia. R. Christensen (Ed.).
150. Strauss RG Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000, 40:1528-1540.
151. Strauss RG Leukocyte reduction to prevent transfusion-transmitted cytomegalovirus infections. Pediatr Transplant 1999, 3(Suppl 1):19-22.
152. Strauss RG Red blood cell transfusion practices in the neonate. Clin Perinatol. 1995, 22:641-655.
153. Strauss RG Selection of white cell-reduced blood components for transfusions during early infancy. Transfusion 1993, 33:352-357.
154. Strauss RG, Levy GJ, et al. National survey of neonatal transfusion practices: II. Blood component therapy. Pediatrics 1993, 91:530-536.
155. Stuart MJ Platelet function in the neonate. Am J Pediatr Hematol Oncol 1979, 1:227-234.
156. Stuart MJ, Dusse J, et al. Differences in thromboxane production between neonatal and adult platelets in response to arachidonic acid and epinephrine. Pediatr Res 1984, 18823-18826.
157. Surgenor DM, Wallace EL, Hao SH, et al. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990, 322:1646-1651.
158. Tanindi S, Kurekci A, et al. The normalization period of platelet aggregation in newborns. Thromb Res 1995, 80:57-62.
159. TRAPSG Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997, 337:1861-1869.
160. Vadhan-Raj S, Murray LJ, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopietin in patients with cancer. Ann Intern Med 1997, 126:673-681.
161. Valentin N, Vergracht A, et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990, 27:73-79.
162. van Gorp EC, Suharti C, et al. Review: infectious diseases and coagulation disorders. J Infect Dis 1999, 180:176-186.
163. Van Hecken A, Juliano ML, et al. Effects of enteric-coated, lowdose aspirin on parameters of platelet function. Aliment Pharmacol Ther 2002, 16:1683-1688.
164. Van Overmeire B, Van de Broek H, et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001, 138:205-211.
165. Vesilind GW, Simpson MB, et al. Evaluation of a centrifugal blood cell processor for washing platelet concentrates. Transfusion 1988, 28:46-51.
166. Vo TD, Cowles J, et al. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus Med 2001, 11:45-47.
167. Voak D, Cann R, et al. Guidelines for administration of blood products: transfusion of infants and neonates. British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus Med 1994, 4:63-69.
168. von dem Borne AE, von Riesz E, et al. Baka, a new platelet-specific antigen involved in neonatal allo-immune thrombocytopenia. Vox Sang 1980, 39:113-120.
169. Vuckovic SA Glanzmann's thrombasthenia revisited. J Emerg Med 1996, 14:299-303.
170. Wandt H, Frank M, et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998, 91:3601-3606.
171. Westman P, Hashemi-Tavoularis S, et al. Maternal DRB1*1501, DQA1*0102, DQB1*0602 haplotype in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GPIIIa-Gln489). Tissue Antigens 1997, 50:113-118.
172. Wilhelm JA, Matter L, et al. The risk of transmitting cytomegalovirus to patients receiving blood transfusions. J Infect Dis 1986, 154:169-171.
173. Williamson LM Transfusion associated graft versus host disease and its prevention. Heart 1998, 80:211-212.
174. Win N, Ouwehand WH, et al. Provision of platelets for severe neonatal alloimmune thrombocytopenia. Br J Haematol 1997, 97:930-932.
175. Wong EC, Luban N Cytomegalovirus and parvovirus transmission by transfusion. Rossi's principles of transfusion medicine 2002, Lippincott, Williams & Wilkins, Philadelphia. D.W. Simon, T.L. Snyder EL, C.P. Stowell, R.G. Strauss (Eds.).
176. Yamreudeewong W, Fosnocht BJ, et al. Severe thrombocytopenia possibly associated with TMP/SMX therapy. Ann Pharmacother 2002, 36:78-82.
177. Yeager AS, Grumet FC, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981, 98:281-287.
178. Zavadil DP, Stammers AH, et al. Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). J Extra Corpor Technol 1998, 30:83-90.
179. Zimmermann R, Schmidt S, et al. Effect of gamma radiation on the in vitro aggregability of WBC-reduced apheresis platelets. Transfusion 2001, 41:236-242.
180. Zwicky C, Tissot JD, et al. Prevention of posttransfusion cytomegalovirus infection: recommendations for clinical practice. Schweiz Med Wochenschr 1999, 129:1061-1066.